報價延遲最少15分鐘:2026/09/05 00:10 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
15.95 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.59/-1.17
|
|
企業價值
229.42M
|
| 資產負債 |
|
每股賬面淨值
0.21
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels. |
